NDA 020699 · Upjohn
Effexor Xr
Venlafaxine Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Oct 20, 1997
Approved uses
11
Original approval plus efficacy supplements
Registered trials
231
58 Phase 3, 14 recruiting
FAERS reports
76,828
52,184 serious, 5,190 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . Effexor XR is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Increased risk of suicidal thoughts and behavior in pediatric patients and young adults taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). • Effexor XR is not approved for use in pediatric patients ( 8.4 ).
What it is approved for
From the label in effect Aug 15, 2023.
Effexor XR is indicated in adults for the treatment of: • Major Depressive Disorder (MDD) [see Clinical Studies (14.1) ] • Generalized Anxiety Disorder (GAD) [see Clinical Studies (14.2) ] • Social Anxiety Disorder (SAD) [see Clinical Studies (14.3) ] • Panic Disorder (PD) [see Clinical Studies (14.4) ] Effexor XR is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with: • Major Depressive Disorder (MDD) ( 1 ) • Generalized Anxiety Disorder (GAD) ( 1 ) • Social Anxiety Disorder (SAD) ( 1 ) • Panic Disorder (PD) ( 1 )
Mechanism: The mechanism of action of venlafaxine in the treatment of MDD, GAD, SAD, and PD is unclear, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 14, 2007 Supplement 47 · Efficacy LabelLetter
- Dec 1, 2005 Supplement 59 · Efficacy LabelLetter
- Nov 18, 2005 Supplement 54 · Efficacy LetterLabel
- Nov 18, 2005 Supplement 57 · Efficacy LabelLetter
- May 5, 2004 Supplement 30 · Efficacy · priority review Letter
- Feb 11, 2003 Supplement 22 · Efficacy LabelLetter
- May 2, 2001 Supplement 15 · Efficacy LabelReviewLetter
- May 2, 2001 Supplement 16 · Efficacy ReviewLabelLetter
- Jul 13, 2000 Supplement 7 · Efficacy
- Mar 11, 1999 Supplement 1 · Efficacy LabelLetter
- Oct 20, 1997 Original approval · Type 3 - New Dosage Form ReviewOther Important Information from FDA
4 products under this application
- EFFEXOR XR · VENLAFAXINE HYDROCHLORIDE EQ 150MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- EFFEXOR XR · VENLAFAXINE HYDROCHLORIDE EQ 75MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- EFFEXOR XR · VENLAFAXINE HYDROCHLORIDE EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, EXTENDED RELEASE, ORAL · Discontinued
- EFFEXOR XR · VENLAFAXINE HYDROCHLORIDE EQ 37.5MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Venlafaxine" as an intervention, any sponsor and status, largest first.
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
- International Study to Predict Optimised Treatment - in DepressionPivotal-lookingStatus unknown
BRC Operations Pty. Ltd.Industry
NCT00693849 · 2,688 participants (planned) · Start Sep 2008 · Primary completion Dec 2019
Drug: Escitalopram; Sertraline and 1 more · For: Major Depressive Disorder
Sites: Colton, California; Mission Viejo, California; Stanford, California · 20 sites in all
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
- Pragmatic Trial of Obsessive-compulsive DisorderPivotal-lookingRecruiting
Shanghai Mental Health CenterAcademic, hospital or other
NCT04539951 · 1,600 participants (planned) · Start Sep 22, 2020 · Primary completion Jun 30, 2027
Drug: Sertraline 200 milligram(mg); Sertraline 300 milligram(mg) and 4 more · For: Obsessive-Compulsive Disorder
Sites: Shanghai, China
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyPivotal-lookingTerminated
ShireTakeda (TAK)
NCT01436175 · 1,570 participants · Start Feb 27, 2012 · Primary completion Mar 27, 2014
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 212 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436149 · 1,262 participants · Start Oct 27, 2011 · Primary completion Dec 23, 2013
Drug: SPD489 (Lisdexamfetamine dimesylate ); Placebo · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Carson, California; Irvine, California · 85 sites in all
- Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed PatientsPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00474708 · 1,151 participants · Start Apr 2007 · Primary completion Mar 2008
Drug: Effexor; SSRI · For: Major Depressive Disorder
Sites: Beijing, China; Guangzhou, China; Zhengzhou, China · 26 sites in all
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT03538691 · 1,149 participants · Start Jul 13, 2018 · Primary completion Jul 8, 2022
Drug: Brexpiprazole; Antidepressant therapy · For: Major Depressive Disorder
Sites: Los Angeles, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective6,585
- nausea6,292
- fatigue5,249
- headache5,249
- depression4,457
- dizziness4,438
- anxiety4,358
- pain3,996
- off label use3,747
- insomnia3,481
- diarrhoea3,363
- malaise3,192
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2,403 |
| 2005 | 2,828 |
| 2006 | 2,585 |
| 2007 | 2,461 |
| 2008 | 2,413 |
| 2009 | 2,745 |
| 2010 | 4,161 |
| 2011 | 3,674 |
| 2012 | 4,406 |
| 2013 | 3,653 |
| 2014 | 3,528 |
| 2015 | 4,697 |
| 2016 | 5,188 |
| 2017 | 4,024 |
| 2018 | 4,040 |
| 2019 | 4,053 |
| 2020 | 3,433 |
| 2021 | 2,965 |
| 2022 | 3,116 |
| 2023 | 2,982 |
| 2024 | 3,043 |
| 2025 | 2,597 |
| 2026 | 1,832 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Effexor XR (Venlafaxine HCl)
2024 spending
$23.8M
Beneficiaries
2,814
16,997 claims
Per beneficiary
$8,449
$18.84 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $30,535,488 |
| 2021 | $27,166,106 |
| 2022 | $26,028,688 |
| 2023 | $26,196,304 |
| 2024 | $23,774,435 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, et al. · Control Clin Trials 2004 · Clinical Trial, Multicenter Study
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis.
Henssler J, Schmidt Y, Schmidt U, et al. · Lancet Psychiatry 2024 · Systematic Review, Meta-Analysis
- Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.
Furukawa TA, Cipriani A, Cowen PJ, et al. · Lancet Psychiatry 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Guaiana G, Meader N, Barbui C, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Probiotics for adults with major depressive disorder compared with antidepressants: a systematic review and network meta-analysis.
Zhao S, Liang S, Tao J, et al. · Nutr Rev 2025 · Systematic Review, Comparative Study
Sponsor: Upjohn
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.